King International Investment (HKSE:00928) Altman Z2-Score: -5.46 (As of Aug. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is King International Investment Altman Z2-Score?

King International Investment HKSE:00928 -4.85% Altman Z2-Score is -5.46 as of Aug. 09, 2026. The stock has 5 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, King International Investment ranks worse than 74.02% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

King International Investment has a Altman Z2-Score of -5.46, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for King International Investment's Altman Z2-Score or its related term are showing as below:

HKSE:00928' s Altman Z2-Score Range Over the Past 10 Years
Min: -7.61   Med: 9.2   Max: 29.27
Current: -5.46

During the past 13 years, King International Investment's highest Altman Z2-Score was 29.27. The lowest was -7.61. And the median was 9.20.


King International Investment  (HKSE:00928) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


King International Investment Altman Z2-Score Related Terms


King International Investment Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for King International Investment's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

King International Investment Altman Z2-Score Chart

King International Investment Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.56 -3.68 -2.95 -7.61 -5.46

King International Investment Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.95 0.00 -7.61 0.00 -5.46

HKSE:00928 vs TMO, DHR, IDXX: Altman Z2-Score Comparison

For the Diagnostics & Research subindustry, King International Investment's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


King International Investment Altman Z2-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, King International Investment's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where King International Investment's Altman Z2-Score falls into.



King International Investment Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

King International Investment's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.6177+3.26*-3.4927+6.72*0.0256+1.05*1.6209
=-5.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was HK$385.2 Mil.
Total Current Assets was HK$383.3 Mil.
Total Current Liabilities was HK$145.4 Mil.
Retained Earnings was HK$-1,345.3 Mil.
Pre-Tax Income was HK$6.8 Mil.
Interest Expense was HK$-3.0 Mil.
Total Liabilities was HK$147.0 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(383.295 - 145.39)/385.165
=0.6177

X2=Retained Earnings/Total Assets
=-1345.281/385.165
=-3.4927

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(6.842 - -3.022)/385.165
=0.0256

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(238.206 - 0)/146.959
=1.6209

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

King International Investment has a Altman Z2-Score of -5.46 indicating it is in Distress Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of -5.46 mean?
King International Investment (HKSE:00928) has a Altman Z2-Score of -5.46 as of Aug. 09, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on King International Investment and its competitors. According to the industry distribution chart, King International Investment ranks #151 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 74%.
Is King International Investment's Altman Z2-Score too high?
King International Investment's current Altman Z2-Score is -5.46. Based on the distribution chart, King International Investment ranks #151 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does King International Investment's Altman Z2-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, King International Investment ranks #151 out of 204 companies for Altman Z2-Score. This places King International Investment in the lower half of its industry. The industry median Altman Z2-Score is 1.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Diagnostics & Research company?
The median Altman Z2-Score among Medical Diagnostics & Research companies is 1.80, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on King International Investment and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z2-Score is 1.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. King International Investment's current Altman Z2-Score is -5.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is King International Investment stock overvalued right now?
Based on GuruFocus' analysis, King International Investment (HKSE:00928) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.04, compared to a current price of HK$0.10 — trading 145% above its estimated fair value. The current Altman Z2-Score is -5.46. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For King International Investment (HKSE:00928), the current Altman Z2-Score is -5.46 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

King International Investment Business Description

Address 15 Queen’s Road Central, 1101, 11th Floor, Gloucester Tower, The Landmark, Hong Kong, HKG
King International Investment Ltd is an investment holding company. Its operating segments include healthcare products and services, money lending, and liquor sales, with the majority of revenue generated from the liquor sales segment. The group provides genetic testing and develops domestic healthcare equipment services. Leveraging its strengths, the group integrates health data analysis software with healthcare equipment to offer new healthcare services and products. Geographically, it derives the majority of its revenue from the PRC.